DI Leu16 IL2

Drug Profile

DI Leu16 IL2

Alternative Names: Anti-CD20 monoclonal antibody-interleukin-2 fusion protein; de-immunized anti-CD20-IL-2 immunocytokine DI-Leu16-IL-2; DI-Leu16-IL2 immunocytokine

Latest Information Update: 22 Dec 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Merck Serono
  • Developer Alopexx Oncology; Provenance Biopharmaceuticals
  • Class Antineoplastics; Immunoglobulin fusion proteins; Monoclonal antibodies; Proteins
  • Mechanism of Action CD20 antigen inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Non-Hodgkin's lymphoma

Most Recent Events

  • 03 Dec 2016 Efficacy, adverse events and immunogenicity data from a phase I trial in Non-Hodgkin's lymphoma (Monotherapy, Second-line therapy or greater) presented at the 58th Annual Meeting and Exposition of the American Society of Hematology (ASH-Hem-2016)
  • 01 Sep 2016 Alopexx Oncology completes a phase I/II trial for non-Hodgkin's lymphoma (Monotherapy, Second-line therapy or greater) in USA (SC) (NCT01874288)
  • 26 Jul 2016 Phase-II clinical trials in Non-Hodgkin's lymphoma (Monotherapy, Second-line therapy or greater) in USA (SC) (Alopexx pipeline, July 2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top